Trial Profile
Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tretinoin (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 29 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 15 Nov 2022 Results published in the Clinical Cancer Research
- 13 Oct 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.